APA
RARE icon

American Portfolios Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

American Portfolios Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-81
Closed -$4.83K – 3588
2022
Q2 		$4.83K Sell
81
-28
-26% -$1.72K ﹤0.01% 2839
2022
Q1 		$7.92K Buy
109
+12
+12% +$835 ﹤0.01% 2782
2021
Q4 		$8.16K Buy
97
+20
+26% +$1.63K ﹤0.01% 2703
2021
Q3 		$6.95K Buy
77
+7
+10% +$633 ﹤0.01% 2716
2021
Q2 		$6.67K Buy
70
+4
+6% +$417 ﹤0.01% 2695
2021
Q1 		$7.51K Buy
66
+32
+94% +$4.36K ﹤0.01% 2513
2020
Q4 		$4.71K Buy
34
+3
+10% +$356 ﹤0.01% 2440
2020
Q3 		$2.55K Buy
+31
New +$2.57K ﹤0.01% 2515
2019
Q4 		– Sell
-472
Closed -$20.2K – 2914
2019
Q3 		$20.2K Buy
472
+9
+2% +$489 ﹤0.01% 1654
2019
Q2 		$29.4K Buy
463
+11
+2% +$700 ﹤0.01% 1498
2019
Q1 		$31.4K Sell
452
-16
-3% -$914 ﹤0.01% 1391
2018
Q4 		$20.3K Buy
+468
New +$25.6K ﹤0.01% 1364

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

American Portfolios Advisors's RARE Position: Q3 2022 in Review

American Portfolios Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2022, closing a stake of 81 shares — an estimated $4.83K sold.

American Portfolios Advisors first reported a position in RARE in Q4 2018 and held it in 12 quarters. The position peaked at $31.4K in Q1 2019. 233 funds tracked by Wall St. Rank hold RARE as of Q3 2022.

  • American Portfolios Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • American Portfolios Advisors sold 81 Ultragenyx Pharmaceutical shares in Q3 2022, an estimated $4.83K.
  • American Portfolios Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2018 and held it in 12 quarters.
  • American Portfolios Advisors's Ultragenyx Pharmaceutical position peaked at $31.4K in Q1 2019.
  • 233 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.